Amie L. Washburn

Fibroblast growth factor inhibits 5α-reductase activity in cultured immature Leydig cells

Abstract The present studies examined the effects of basic fibroblast growth factor (bFGF) on 5α-reductase activity of cultured Leydig cells from immature rats. Basic FGF inhibited both hCG- and 8-bromo-cyclic AMP-stimulated 5α-reductase activity in a dose-dependent manner; however, it had little or no effect on basal enzyme activity. Inhibition was achieved with as little as 0.1 ng/ml bFGF, and maximal inhibition was observed with 10 ng/ml bFGF. These studies suggest that locally produced bFGF may play a role in modulating the age-dependent decline in 5α-reductase activity in Leydig cells.

Basic fibroblast growth factor inhibits Δ5-3β-hydroxysteroid dehydrogenase-isomerase activity in cultured immature Leydig cells

Basic fibroblast growth factor inhibited basal delta 5-3 beta-hydroxysteroid dehydrogenase-isomerase activity in cultured Leydig cells from immature rats in a concentration- and time-dependent manner. Maximal inhibition was achieved with 5-10 ng/ml basic fibroblast growth factor following approximately 48 h of exposure. The inhibition of basal delta 5-3 beta-hydroxysteroid dehydrogenase-isomerase activity was not altered by human chorionic gonadotropin; however, cycloheximide (0.5-2.0 micrograms/ml) partially reversed the effects of basic fibroblast growth factor in a dose-dependent manner. These studies suggest that locally-produced basic fibroblast growth factor may modulate Leydig cell testosterone formation by regulating delta 5-3 beta-hydroxysteroid dehydrogenase-isomerase activity.

Platelet derived growth factor inhibits 5α-reductase and Δ5-3β-hydroxysteroid dehydrogenase activities in cultured immature Leydig cells

Platelet derived growth factor inhibited both hCG- and 8-Br-cAMP-stimulated 5 alpha-reductase activity in cultured immature Leydig cells in a dose-dependent manner, while not significantly inhibiting basal enzyme activity. Platelet derived growth factor also inhibited basal delta 5-3 beta-hydroxysteroid dehydrogenase activity and hCG-stimulated testosterone formation. Maximal inhibitions were achieved with 10 ng/ml of platelet derived growth factor. These studies suggest that platelet derived growth factor should be included among the variety of locally produced regulatory factors which modulate Leydig cell function.

Evidence for basic fibroblast growth factor receptors in cultured immature leydig cells

Previous studies have shown that basic fibroblast growth factor (bFGF) can modulate basal and luteinizing hormone/human chorionic gonadotropin (LH/hCG)-stimulated Leydig cell functions. It has not been ascertained whether these actions are due to direct or indirect effects on Leydig cells. To resolve this question, a multi-step procedure was used to isolate highly-purified Leydig cells from immature rats. 125I-bFGF binding studies were performed on cultured cells. Scatchard analysis of the data indicated a single binding site with an apparent Kd of 82 pM and a binding capacity of approximately 2800 sites per cell. Both bFGF and acidic FGF similarly were effective in displacing 125I-bFGF, suggesting that the receptor binds both bFGF and aFGF. However, neither hCG, follicle-stimulating hormone (FSH), insulin, insulin-like growth factor-1 (IGF-1), prolactin, platelet-derived growth factor (PDGF) or epidermal growth factor (EGF) were effective competitors. When binding studies were conducted on cultured testicular interstitial cellular fractions that are normally discarded during Leydig cell purification, bFGF receptors were identified in these fractions. These results demonstrate that bFGF can have direct effects on Leydig cells through specific receptors; however, because other interstitial cell type(s) also have bFGF receptors, they stress the importance of using highly purified cells when evaluating bFGF actions on Leydig cells.

Effects of acidic fibroblast growth factor on 5-ene-3β-hydroxysteroid dehydrogenase-isomerase and 5α-reductase activities and [125I]human chorionic gonadotrophin binding in cultured immature Leydig cells

The present studies examined the effects of acidic fibroblast growth factor (aFGF) on 5-ene-3 beta-hydroxysteroid dehydrogenase-isomerase (3 beta-HSD) and 5 alpha-reductase activities and [125I]human chorionic gonadotrophin ([125I]hCG) binding in cultured immature rat Leydig cells. Increasing concentrations of aFGF (0.1-20 ng/ml) progressively decreased basal 3 beta-HSD activity from 0.474 +/- 0.0335 to 0.093 +/- 0.0004 nmol progesterone/30 min/10(5) cells. This inhibition by aFGF (10 ng/ml) was partially reversed by 1 micrograms/ml insulin or 100 ng/ml insulin-like growth factor-I. Increasing aFGF concentrations (0.1-10 ng/ml) also inhibited hCG-stimulated 5 alpha-reductase activity in a dose-dependent manner, but had only a modest effect on basal enzyme activity. Increasing aFGF (0.1-200 ng/ml) also progressively inhibited [125I]hCG binding in cultured immature Leydig cells. These studies demonstrate a similarity in the inhibitive effects of aFGF with bFGF effects on 3 beta-HSD and 5 alpha-reductase activities and [125I]hCG binding to LH receptors, although, generally, higher aFGF concentrations were required to elicit maximal inhibitive effects. However, a FGF differed from the actions of bFGF on 3 beta-HSD activity and LH receptor levels in that a secondary increase with higher growth factor concentrations was not observed.

Biphasic effect of basic fibroblast growth factor on 125I-human chorionic gonadotropin binding to cultured immature Leydig cells

The present studies examined the effects of basic fibroblast growth factor (bFGF or FGF-2) on 125I-human chorionic gonadotropin (hCG) binding to cultured immature rat Leydig cells. We found that low concentrations of bFGF (0.1-1.0 ng/ml) inhibited 125I-hCG binding to cultured immature Leydig cells in a dose- and time-dependent manner; however, this inhibition was reversed partially at higher bFGF concentrations (10-200 ng/ml). The decline in 125I-hCG binding by bFGF was due to a reduction in the number of binding sites per cell and not to a change in receptor affinity for the ligand. The inclusion of 10 micrograms/ml heparin (a concentration that is reported to block bFGF binding to heparan sulfate proteoglycans) with increasing bFGF concentrations had no effect on the inhibition of 125I-hCG binding by low bFGF concentrations, but completely blocked the secondary increase in binding by higher bFGF concentrations. In addition, neither varying heparin concentrations (0.1-25 micrograms/ml) nor insulin or insulin-like growth factor-I had any effect on the inhibition of 125I-hCG binding by 1 ng/ml bFGF. These studies suggest that receptor-mediated actions of bFGF (inhibition of hCG binding by low bFGF concentrations) on cultured immature Leydig cells are unaffected by heparin; however, the secondary increase in 125I-hCG binding observed with higher bFGF concentrations (mediated by bFGF binding to heparan sulfate proteoglycans) is blocked by heparin.

Evidence that both receptor- and heparan sulfate proteoglycan-bound basic fibroblast growth factor are internalized by cultured immature Leydig cells

The present studies examined how 125I-labeled basic fibroblast growth factor (bFGF) bound to high affinity receptors and with lower affinity to heparan sulfate proteoglycans (HSPG) of cultured immature rat Leydig cells was processed. Following incubation for 2 h at 4 degrees C with 125I-bFGF, cells were washed to remove unbound radioactivity. Fresh medium was added, and cells were incubated at 4 degrees and/or 37 degrees C. At time zero and at specific intervals over the next 6 h, the incubation medium was saved and cells washed to quantitate 125I-bFGF released into the medium, associated with HSPG of the cell surface or extracellular matrix (radioactivity released by washing cells with 2 M NaCl, pH 7.4), associated with cell surface receptors (radioactivity released by washing cells with 2 M NaCl, pH 4.0) or internalized (radioactivity resistant to high salt and acid washes, and solubilized with 0.5 M NaOH). Radioactivity released into the initial medium and the pooled washes was further divided into a trichloroacetic acid (TCA)-precipitated form (radioactivity precipitated by 10% TCA) and a TCA-soluble form (radioactivity remaining in the TCA supernatant). 125I-bFGF associated with both HSPG and surface receptors declined progressively during the first 4 h of incubation before stabilizing when cells were transferred to 37 degrees C. These declines were associated with a corresponding increase in intracellular 125I-bFGF. These changes were blocked by maintaining cells at 4 degrees C. The majority of internalized 125I-bFGF appeared to originate from the HSPG-bound fraction as there was a greater decline in HSPG-associated radioactivity and most of the increase in internalized radioactivity could be blocked by the inclusion of 10 micrograms/ml heparin (which mainly blocks 125I-bFGF binding to HSPG but not to high affinity receptors) during the initial incubation with 125I-bFGF for 2 h at 4 degrees C. Furthermore, HSPG-mediated internalization appeared to have two components: the major fraction was blocked by the inclusion of 10 micrograms/ml heparin, while a heparin-resistant fraction, appeared to be closely linked both quantitatively and temporarily to receptor-mediated internalization. A minor fraction of internalized 125I-bFGF was metabolized in lysosomes, as the inclusion of 50 microM chloroquine during the 6 h incubation at 37 degrees C inhibited most of the increase in TCA-soluble radioactivity appearing in the incubation medium.(ABSTRACT TRUNCATED AT 400 WORDS)

Enhanced stimulation of 5α-reductase activity in cultured Leydig cell precursors by human chorionic gonadotropin

Previous studies have demonstrated that the increase in number of Leydig cells during prepubertal maturation results, in part, from the differentiation of mesenchymal precursors between the second and fourth week of postnatal life. After conversion to immature Leydig cells, they actively synthesize testosterone, but this androgen does not accumulate because high 5 alpha-reductase activity rapidly converts testosterone to 5 alpha-reduced metabolites. The present studies examined whether the conversion of precursor cells to immature Leydig cells in vitro by human chorionic gonadotropin (hCG), as characterized by progressive increases in testosterone formation and 5-ene-3 beta-hydroxysteroid dehydrogenase-isomerase (3 beta-HSD) activity, is associated similarly with an enhanced stimulation of 5 alpha-reductase activity. We also evaluated whether this conversion occurs following blockade of dihydrotestosterone (DHT) formation by the inclusion of a 5 alpha-reductase inhibitor during the entire treatment period. Precursor cells were isolated from immature rats using a multi-step procedure normally used to isolate highly purified Leydig cells from adult or immature rats. These cells localize in a region of lower density on Percoll gradients than Leydig cells. Although the acute (3h) response to hCG with respect to testosterone formation, and basal 3 beta-HSD and 5 alpha-reductase activities on day 1 of culture were much higher in purified Leydig cells than precursor cells from immature rats, the response of each parameter to chronic (6-day) treatment with hCG was much greater in precursor cells. Furthermore, the conversion of precursor cells to immature Leydig cells occurred in the presence of a 5 alpha-reductase inhibitor during the entire treatment period, suggesting that this conversion occurs in the absence of DHT. These results demonstrate for the first time that in addition to increased testosterone biosynthesis and 3 beta-HSD activity, the conversion of precursor cells to immature Leydig cells, in vitro, in response to chronic hCG treatment, involves enhanced 5 alpha-reductase activity.

Evidence that Leydig precursors localize in immature band two cells isolated on Percoll gradients

The present studies examined responses to hCG and/or insulin of 3 beta-hydroxy-5-ene-steroid dehydrogenase and steroid 5----4-ene-isomerase activity (3 beta-HSD) in cultured Band 2 and Band 3 cells from 25- to 40-day-old rats isolated on Percoll gradients. In Band 2 cells, from 25-day-old rats enzyme activity increased about 3- and 2.5-fold, after 6 days of exposure to hCG or insulin, respectively. However, hCG did not stimulate enzyme activity in Band 2 cells from 30-, 35- and 40-day-old animals, and responses to insulin alone or insulin plus hCG declined with age. In Band 3 cells only insulin increased enzyme activity at each age. Neither hCG or insulin altered DNA levels in Band 2 or Band 3 cells, suggesting that increased activity in Band 2 cells from 25-day-old rats was not due to cellular replication. However, hCG increased the number of cells staining positive for 3 beta-HSD about 4-fold in Band 2 cells from 25-day-old rats. Insulin did not increase the number of positive staining cells in Band 2 and Band 3 cells from 25-day-old rats, suggesting that its major effect was to increase enzyme activity in existing cells. These results suggest that during a limited period of maturation precursor cells in Band 2, which are undetected by histochemical staining for 3 beta-HSD, can be converted to Leydig cells in culture by hCG.

Basic fibroblast growth factor-induced increase in 125I-human chorionic gonadotropin binding to luteinizing hormone receptors in cultured immature leydig cells is mediated by binding to heparan sulfate proteoglycans

Previous studies have shown that basic fibroblast growth (bFGF) has a biphasic effect on 125I-hCG binding to LH receptors in cultured Leydig cells from immature rats. Low concentrations of bFGF (0.1-1.0 ng/ml) progressively decreased binding, while higher concentrations (10-100 ng/ml) progressively increased binding above nadir levels. In the present studies, treatment of cultured immature Leydig cells with heparinase I and/or heparinase III, which enzymatically remove heparan sulfate proteoglycans, had no effect on basal binding of 125I-hCG to LH receptors or the decrease in binding due to treatment with low bFGF concentrations; however, this treatment dramatically reduced the secondary increase in binding following the addition of higher bFGF concentrations. These results strongly support the idea that the secondary increase in 125I-hCG binding to LH receptors elicited by treatment with higher bFGF concentrations is mediated by bFGF binding to heparan sulfate proteoglycans associated with the plasma membrane and/or extracellular matrix.